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Schiff bases and their Ru(II) metallates with potent
antiproliferative activity and enhanced LDH and NO
release†
G. Kalaiarasi,a S. Rex Jeya Rajkumar,b S. Dharani,a J. G. Małeckic
and R. Prabhakaran *a
New cyclometallated ruthenium(II) complexes of 3-acetyl-7-methoxycoumarin-4N-substituted
thiosemicarbazones were synthesized and characterized by analytical and spectral techniques. The
crystal structures of the ligands H2L
1–3 and complexes (1, 2 and 4) were confirmed by X-ray
crystallography. The analysis showed that the ligands have undergone C–H activation at the C(4) carbon
of the pyrone ring and acted in a tridentate fashion by binding through C, N and S atoms. CT-DNA and
protein (BSA/HSA) binding studies were carried out to analyze their interaction with biomolecules. Good
binding affinity with DNA was observed with intercalative binding mode, which was further confirmed by
EB displacement and viscosity measurement studies. The quenching mechanism with BSA/HSA was
found to be static. Three dimensional (3D) fluorescence measurements were carried out to validate the
micro environmental changes in the serum albumins. Their antioxidant propensity and antimicrobial
study insisted that the compounds displayed good spectrum of activity. Evaluation of their anticancer
potential against MCF-7 (human breast cancer) and A549 (human lung carcinoma) cell lines revealed that
the complexes exhibited better activity than the ligands and cisplatin. Further, the results of LDH and NO
release assays supported the cytotoxic nature of the compounds. The non-toxic nature of the
compounds was established by testing against the non-cancerous cell line HaCaT (human normal
keratinocyte).Introduction
Thiosemicarbazides are a versatile class of compounds with
indispensable properties such as antitumor, antifungal, anti-
bacterial, antiviral, antiparasitic, etc.1–6 They are N, S donor
ligands whose activity can be greatly enhanced by the presence
of additional donor sites and a variety of coordination modes
can be shown by these systems.7–9 Potential ligands are formed
by attaching thiosemicarbazides with carbonyl compounds
having a heterocyclic moiety. A good deal of research can be
possible on such ligands and their metal complexes.10 It isrsity, Coimbatore 641 046, India. E-mail:
387; Tel: +91-422-2428319
Karunya University, Coimbatore 641 114,
niversity, Szkolna 9, 40-006 Katowice,
ESI) available: Crystallographic data for
. CCDC 1580118 (H2L
1), 1580119 (H2L
2),
(2) and 1580123 (4). For ESI and
ther electronic format see DOI:
hemistry 2018already reported that the cytotoxicity of thiosemicarbazones is
mostly related with their parent aldehyde or ketone, metal
chelation efficacy and terminal amino substitution.11,12
Coumarin is one among the natural products found extensively
in plants, which exhibits various pharmacological activities.13,14
Coumarin derived antibiotics such as novobiocin, clorobiocin
and coumermycin A1 are commercialized.15,16 Their ability to
inhibit human immunodeciency virus integrase made them to
be analysed in the treatment of HIV.17 Reports are available for
testing coumarin derivatives against various tumor18 and
neuronal cell lines.19 Generation of satisfactory clinical
compounds is one of the promising approaches to attain
effective and less toxic chemodrugs. The present scenario of
inorganic research faces difficulties in raising highly active
metal based drugs, the main criteria of which being less toxic
and target specic. Among others, cancer stands as the most
threatening disease and consistent attempts are made to
develop appropriate chemotherapeutic drugs. Successful
application of cisplatin as an anticancer agent provoked the
chemists to search for other active metal complexes.20,21
Recently, ruthenium complexes have come into the lime light
since two such complexes namely NAMI-A22 and KP1019 23RSC Adv., 2018, 8, 1539–1561 | 1539
RSC Advances Paperentered into clinical trials, attesting the efficiency of ruthenium
in the treatment of cancer. Moreover, exhibition of diverse
coordination modes, stable oxidation states (from 2 to 8) and
mimicking iron in binding biomolecules makes ruthenium
a better alternative for platinum.24 Sufficient number of articles
are available in the literature reporting the anticancer efficiency
of ruthenium complexes including those by Garza-Ortiz et al.,25
and Juinn Chow et al.26
Considering the foregoing facts and our continuous inves-
tigation on thiosemicarbazone complexes of various transition
metals, herein we report the synthesis, spectral characteriza-
tion, X-ray diffraction analysis, DNA/protein binding, antioxi-
dant, antimicrobial and anticancer studies of 3-acetyl-7-
methoxycoumarin-4N-substituted thiosemicarbazones and
their cyclometallated ruthenium(II) complexes.Results and discussion
Synthesis and characterization
The ligands H2L
1–4 were synthesized by the reaction of 3-acetyl-
7-methoxy-2H-chromene-2-one with 4(N)-substituted thio-
semicarbazides in methanol, which was precipitated as yellow
solid from the reaction mixture. Reacting an equimolar mixture
of these Schiff base ligands with [RuHClCO(PPh3)3] in benzene
under reux for 7 h afforded a reddish orange solution
(Scheme 1). Characterization of the ligands and complexes were
done by using elemental analyses, infrared spectroscopy, UV-Vis
and NMR spectroscopy. The structures of the ligands H2L
1–3
and complexes (1, 2 and 4) were conrmed by X-ray crystallo-
graphic study. X-ray crystal structural determination clearly
showed that the ligands have undergone C–H activation at the
ortho position of H3C–C]N and acted in a tridentate, bianionic
manner binding through CNS atoms. Both the ligands and
complexes are air stable and soluble in ethanol, chloroform,Scheme 1 Synthesis of the ligands H2L
1–4 and their new ruthenium(II) c
1540 | RSC Adv., 2018, 8, 1539–1561dichloromethane, toluene, methanol, DMSO and DMF. By
using UV-visible spectroscopic techniques, the stability of the
compounds in aqueous solutions was conrmed (Fig. S1 in the
ESI†). The spectra recorded immediately and aer 24 h did not
show any appreciable change in the intensity and the position
of the bands.
Assignments of selected characteristic IR band positions
provided signicant indication for the formation of 3-acetyl-7-
methoxycoumarin-4(N)-substituted thiosemicarbazone ligands
and their ruthenium complexes (Fig. S2–S10†). A band in the
region 1600–1644 cm1 is assigned to the n(C]N),27 whereas the
shiing of this band to 1606–1607 cm1 revealed the coordina-
tion of azomethine nitrogen atom to the metal ion.28,29 A band
appeared at 826–835 cm1 in the ligands due to vibration of the
C]S group, which disappeared in the spectra of the complexes
and a new band corresponding to the C–S group appeared at 744–
745 cm1 indicating that the other coordination is through thi-
olate sulphur aer enolization followed by deprotonation.30 In all
the complexes, terminally coordinated carbonyl group appeared
as a strong band in the region 1918–1925 cm1.29,30 The stretch-
ing frequencies of triphenylphosphine group were observed
around 1404–1434, 1087–1090, 694–696 cm1.30,31
The electronic spectra of the ligands H2L
1–4 and complexes
1–4 were recorded in DMSO. In the spectra of the free ligands,
the higher energy absorption bands appeared around 275–
282 nm have been assigned to (p / p*) transitions and the
bands observed at 352–356 nm have been assigned to (n/ p*)
transitions.32 In the complexes 1–4, the high energy absorption
band observed in the region 268–337 nm has been assigned to
intra ligand transitions, the lowest energy band in the region
357–380 nm has been attributed to the ligand to metal charge
transfer (LMCT) transitions.7
The 1H NMR spectra of 3-acetyl-7-methoxy-coumarin, 3-
acetyl-7-methoxy-coumarin-4(N)-substitutedomplexes.
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advancesthiosemicarbazone ligands H2L
1–4 and their Ru(II) complexes
(1–4) showed the signals in the expected regions (Fig. S11–S19†).
The singlets that appeared at d 10.26–10.77 ppm were assigned
to the hydrazinic proton of the free ligands, these signals were
absent in the complexes (1–4), supporting the enolization and
deprotonation of the NH–C]S group upon coordination of the
thiolate sulfur to the Ru(II) ion.7,30 The singlet due to the N]C–
CH3 proton appeared at d 2.24–2.33 ppm in the spectra of free
ligand, which underwent an upeld shi in the spectra of the
complexes to d 1.88–2.09 ppm, suggesting that the coordination
occurred via the nitrogen atom of N]C–CH3 group.29,33,34 The
spectra of the ligands H2L
1–4 displayed a singlet at d 7.98–
8.45 ppm, which is corresponding to the hydrogen atom at C(4)
carbon, however, for complexes 1–4 no resonance could be
attributed to C4(H), which indicated that the C(4) carbon atom
of the pyrone ring is coordinated to the metal aer deprotona-
tion. In addition, the spectra of all the ligands and complexes
exhibited a series of signals for aromatic protons at d 6.29–
7.74 ppm 7,30 and a singlet for –OCH3 protons around d 3.74–
3.93 ppm.35
X-ray crystallography
Crystal structure of the ligands H2L
1–3. The molecular
structures of the ligandsH2L
1–3 have been determined by single-
crystal X-ray diffraction studies. A summary of the structureTable 1 Crystallographic data of ligands H2L
1, H2L
2 and H2L
3
Identication code [H2-7MAC-tsc]
Empirical formula C13H13N3O3S$CH3OH
Formula weight 323.36
Temperature 295(2) K
Wavelength 0.7107 A˚
Crystal system Triclinic
Space group P1
Unit cell dimensions
a 8.3702 (6) A˚
B 8.8979(8) A˚
C 12.4669 (9) A˚
a 97.411 (7)
b 106.008 (6)
g 113.670 (8)
Volume 786.53 (12) A˚3
Z 2
Density 1.365 mg m3
Absorption coefficient 0.227 mm1
F(000) 340
Crystal size 0.02  0.08  0.34 mm
Crystal shape Needle
q range for data collection 4.223 to 27.424
Limiting indices 11 # h # 11, 12 # k # 12,
16 # l # 17
Reections collected 2480
Independent reections 3726 (R(int) ¼ 0.0307)
Completeness to q 26.32
Absorption correction Multi-scan
Renement method Full-matrix least-squares on F2
Data/restraints/parameters 3726/0/215
Goodness-of-t on F2 1.042
Final R indices [I > 2s(I)] R1 ¼ 0.0841, wR2 ¼ 0.1760
R indices (all data) R1 ¼ 0.0984, wR2 ¼ 0.2032
This journal is © The Royal Society of Chemistry 2018renement of the ligands is listed in Table 1 and selected inter
atomic distances and bond angles are summarized in Table S1.†
The structure of the ligand H2L
1 together with the atom label-
ling scheme is shown in Fig. 1. The ligand H2L
1 crystallized in
the triclinic system with P1 space group. The monomeric units
of the ligand H2L
1 were arranged in a dimeric manner by the
weaker N(1)–H(1)/O(1) hydrogen bonds (Fig. S20, Table S2†).
The ligandH2L
2 crystallized in the trigonal system with P3 space
group. Six crystallographically independent molecules were
present in the unit cell. In ligand H2L
2, we found the donor–
acceptor distance as 3.013 A˚ corresponding to the N(1)–O(1) and
O(1)–N(1) bond between the two molecules (Fig. 2). This inter-
action gave a pseudo bimolecular appearance to the ligandH2L
2
(Fig. S21†). The X-ray single crystal structure of the ligand H2L
3
is shown in Fig. 3. From the symmetry of the reections and
solution of the structures, it is clear that the crystals belong to
the triclinic P1 space group. H-Bonding in this structure is
distinctly different from that observed in H2L
1 and H2L
2. The
ligand H2L
3 involved an intramolecular dipolar interaction
between coumarin oxygen (O2) and azomethine nitrogen (N3)
atoms as shown in Fig. S22 (Table S2†).
The existence of thione form in the ligands is conrmed by
the C]S bond lengths, which are of 1.696 (3) A˚, 1.677 (3) A˚ and
1.671 (4) A˚ for H2L
1, H2L
2 and H2L
3 respectively and the bond
length of C]N group (C(2)–N(3) ¼ 1.289(3) A˚ for H2L1, C(3)–[H2-7MAC-mtsc] [H2-7MAC-etsc]
C14H15N3O3S C15H17N3O3S
305.35 319.38
295(2) K 295(2) K
0.7107 A˚ 0.7107 A˚
Trigonal Triclinic
P3 P1
17.5595 (9) A˚ 7.5260 (6) A˚
17.5595 (9) A˚ 8.0281 (6) A˚
8.6657 (7) A˚ 13.5383 (10) A˚
90 89.670 (6)
90 87.437 (6)
120 67.782 (7)
2314.0 (3) A˚3 756.43 (11) A˚3
6 2
1.315 mg m3 1.402 mg m3
0.223 mm1 0.230 mm1
960 336
0.06  0.08  0.31 mm 0.13  0.14  0.38 mm
Needle Prism
4.003 to 25.505 4.100 to 28.715
22 # h # 24, 24 # k # 23,
7 # l # 11
10 # h # 10, 11 # k # 10,
17 # l # 17
2007 2619
3576 (R(int) ¼ 0.0321) 3626 (R(int) ¼ 0.0427)
26.32 26.32
Multi-scan Multi-scan
Full-matrix least-squares on F2 Full-matrix least-squares on F2
3576/0/201 3626/0/203
1.007 1.055
R1 ¼ 0.0553, wR2 ¼ 0.1094 R1 ¼ 0.0889, wR2 ¼ 0.2249
R1 ¼ 0.1141, wR2 ¼ 0.1298 R1 ¼ 0.1151, wR2 ¼ 0.2422
RSC Adv., 2018, 8, 1539–1561 | 1541
Fig. 1 ORTEP diagram of [H2-7MAC-tsc] (H2L
1).
Fig. 2 ORTEP diagram of [H2-7MAC-mtsc] (H2L
2).
RSC Advances PaperN(3) ¼ 1.285(3) A˚ for H2L2, C(4)–N(3) ¼ 1.273(5) A˚ forH2L3) is in
agreement with a formal C]N bond length.36 In the ligands
H2L
1–3, the thione sulfur atom S(1) is trans to the N(3) nitrogen
atom of C]N group about C(1)–N(2) bond, this structural
arrangement corresponds to E-isomer, which is conrmed by
a torsion angle of S(1)–C(1)–N(2)–N(3) bond, 179.6(2) for H2L
1,
178.1(2) for H2L
2 and 176.6(3) for H2L
3. The bond distances in
the 3-acetyl-7-methoxy-4(N)-thiosemicarbazones H2L
1–3 agree
well with the values observed for other
thiosemicarbazones.27,37,38Fig. 3 ORTEP diagram of [H2-7MAC-etsc] (H2L
3).
1542 | RSC Adv., 2018, 8, 1539–1561Crystal structure description of new Ru(II) complexes. The
molecular structures of the complexes (1, 2 and 4) have been
determined by single crystal X-ray crystallographic studies to
conrm the coordination modes of the 3-acetyl-7-methoxy-2H-
chromene-2-one 4(N)-substituted thiosemicarbazones in the
complexes. The summary of the data collection and the
renement parameters have been given in Table 2 whereas
selected bond lengths and bond angles are given in Table S3.†
The ORTEP view along with the atomic numbering scheme of
complexes 1, 2 and 4 are given in Fig. 4–6. The X-ray crystal
structures revealed that the complexes 1, 2 and 4 crystallized inThis journal is © The Royal Society of Chemistry 2018
Table 2 Crystallographic data of complexes 1, 2 and 4
Identication code [Ru(7-MAC-tsc)(CO)(PPh3)2] (1) [Ru(7-MAC-mtsc)(CO)(PPh3)2] (2) [Ru(7-MAC-ptsc)(CO)(PPh3)2] (4)
Empirical formula C50H41N3O4P2RuS$CH3OH C51H43N3O4P2RuS C56H45N3O4P2RuS
Formula weight 974.97 956.95 1019.02
Temperature 295(2) K 295(2) K 295(2) K
Wavelength 0.7107 A˚ 0.7107 A˚ 0.7107 A˚
Crystal system Triclinic Triclinic Triclinic
Space group P1 P1 P1
Unit cell dimensions
a 13.0569 (5) A˚ 12.2016 (7) A˚ 13.3038 (5) A˚
B 13.7232 (5) A˚ 13.4519 (7) A˚ 13.4870 (5) A˚
C 13.8479 (5) A˚ 15.1541 (9) A˚ 14.3074 (5) A˚
a 89.094 (3) 82.857 (4) 85.881 (5)
b 75.301 (3) 79.550 (5) 85.582 (5)
g 70.576 (3) 65.934 (5) 69.949 (3)
Volume 2257.10 (15) A˚3 2229.9 (2) A˚3 2401.56 (16) A˚3
Z 2 2 2
Density 1.435 mg m3 1.425 mg m3 1.409 mg m3
Absorption coefficient 0.516 mm1 0.520 mm1 0.487 mm1
F(000) 1004 984 1048
Crystal size 0.02  0.15  0.24 mm 0.08  0.22  0.26 mm 0.01  0.13  0.31 mm
Crystal shape Plate Plate Plate
q range for data collection 3.793 to 28.999 3.605 to 28.757 3.857 to 29.163
Limiting indices 15 # h # 17, 17 # k # 18,
14 # l # 18
15 # h # 16, 17 # k # 18,
18 # l # 19
17 # h # 17, 18 # k # 18,
19 # l # 15
Reections collected 8354 7740 8210
Independent reections 10 636 (R(int) ¼ 0.0334) 10 577 (R(int) ¼ 0.067) 11 129 (R(int) ¼ 0.0376)
Completeness to q 26.32 26.32 26.32
Absorption correction Multi-scan Multi-scan Multi-scan
Renement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 Full-matrix least-squares on F2
Data/restraints/parameters 10 636/0/580 10 577/0/562 11 129/0/610
Goodness-of-t on F2 1.034 1.092 1.016
Final R indices [I > 2s(I)] R1 ¼ 0.0390, wR2 ¼ 0.0833 R1 ¼ 0.0839, wR2 ¼ 0.2024 R1 ¼ 0.0425, wR2 ¼ 0.0824
R indices (all data) R1 ¼ 0.0582, wR2 ¼ 0.0924 R1 ¼ 0.1085, wR2 ¼ 0.2330 R1 ¼ 0.0689, wR2 ¼ 0.0916
Paper RSC Advancesthe triclinic P1 space group. In the complexes, the ligands
coordinated to the ruthenium ion through the N(1) nitrogen,
pyrone carbon C(3) and thiolate sulphur atoms, forming two
ve member chelate rings with a bite angle N(1)–Ru(1)–S(1) of
78.39(6) for complex 1, 78.90(1) for complex 2, 79.38(6) for
complex 4, and a bite angle of C(5)–Ru(1)–N(1) of 78.58(8) for
complex 1, 78.10(2) for complex 2, C(13)–Ru(1)–N(1) of
78.18(9) for complex 4. The fourth site is occupied by the
carbon atom of the carbonyl group to form a CNSC square-
plane. The carbonyl group occupied the site trans to the N1
nitrogen, which is conrmed from the bond angle N(1)–Ru(1)–
C(1) of 179.0(1) for complex 1, 177.5(2) for complex 2, and
178.10(2) for complex 4 and bond length of Ru(1)–C(1)
distances of 1.846(2) A˚ for complex 1, 1.853(4) A˚ for complex 2
and 1.848(2) A˚ for complex 4 found similar to the reported
complexes.29 The remaining axial coordination sites are lled
up by phosphorous atoms of two triphenylphosphine ligands,
which are mutually trans to each other with Ru(1)–P(1) and
Ru(1)–P(2) distances of 2.379(8) A˚ and 2.376(8) A˚ for complex 1,
2.365(1) A˚ and 2.383(1) A˚ for complex 2 and 2.376(8) A˚ and
2.376(8) A˚ for complex 4 and are slightly bent towards the
carbonyl group due to the steric requirements of somewhat
bulky chelating ligand, causing a slight deviation from a linear
trans arrangement, which is evident from the bond angle ofThis journal is © The Royal Society of Chemistry 2018P(1)–Ru(1)–C(1) 89.41(8) for complex 1, 88.3(1) for complex 2,
90.17(8) for complex 4, are smaller than bond angle of P(1)–
Ru(1)–N(1) ¼ 90.25(6) for complex 1, P(1)–Ru(1)–N(1) ¼
93.3(1) for complex 2, P(1)–Ru(1)–N(1) ¼ 90.94(6) for
complex 4, and P(2)–Ru(1)–N(1) ¼ 93.40(6) for complex 1,
P(2)–Ru(1)–N(1) ¼ 89.2(1) for complex 2, P(2)–Ru(1)–N(1) ¼
89.94(6) for complex 4. The observed bond distances of Ru–P
are comparable with those found in other reported ruthenium
complexes containing triphenylphosphine.7,29,30,39–41 The bond
distances of Ru(1)–P(1) and Ru(1)–P(2) are comparatively
longer than those observed for basal planar bonds, such as
Ru(1)–N(1) [2.077–2.097 A˚], Ru(1)–Cpyrone [2.062–2.077 A˚] and
Ru(1)–C(1) [1.851–1.87 A˚]. Due to the variation in the bond
length and bond angles, ruthenium(II) ion sitting in a CNOSP2
coordination environment and adopted a distorted octahedral
geometry. The selected bond distances of complexes (1, 2 and
4) such as Ru–P, Ru–O, Ru–S, Ru–N and Ru–C and bond angles
agree very well with the similar reported ruthenium(II)
complexes.7,29–31,37,39–41
While dealing with the hydrogen-bonding interactions, in
the complexes 2 and 4, we found the donor–acceptor distance
(2.954 for (2), 3.054 A˚ for (4)) corresponding to the O(4)–O(4)
bond between the carbonyl oxygen atom of the rst molecule
and with the second molecule. This interaction gave a pseudoRSC Adv., 2018, 8, 1539–1561 | 1543
Fig. 4 ORTEP diagram of [Ru(7MAC-tsc)CO(PPh3)2] (1).
Fig. 5 ORTEP diagram of [Ru(7MAC-mtsc)CO(PPh3)2] (2).
1544 | RSC Adv., 2018, 8, 1539–1561 This journal is © The Royal Society of Chemistry 2018
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Fig. 6 ORTEP diagram of [Ru(7MAC-ptsc)CO(PPh3)2] (4).
Paper RSC Advancesbinuclear structural appearance to the complex (2) and (4)
(Fig. S23–S24; Table S2†).DNA binding studies
UV-Vis absorption spectral titrations. DNA-binding studies
are important for the rational design and construction of new
and more efficient drugs targeted to DNA.42 The binding affinity
of the ligands and their organoruthenium(II) complexes with CT-
DNA can be measured by using UV-Vis spectroscopy. The UV-Vis
absorption spectra of the free ligands and their complexes in the
absence and presence of CT DNA are given in Fig. S25† and 7. In
the presence of DNA, the absorption bands at about 345–349 nm
for the ligands H2L
1–4 exhibited hypochromism of about 41.46–
48.41% accompanied by a small red shi. When the concentra-
tion of DNA is increased, all the new organoruthenium(II)
complexes (1–4) showed a decrease in absorbance in the charge
transfer band at 330–348 nm to the extent of about 48.91–53.07%
with a red-shi (bathochromic shi) of 2–8 nm. The decrease in
absorbance with increase in concentration of CT-DNA may be
due to the decrease in transition probabilities as a result of
partial transfer of electrons from the p orbital of the DNA base
pairs to the coupled p* orbital of the coordinated Schiff base to
metal due to overlapping.43 The extent of hypochromism in the
charge transfer band is an indication of the strength of inter-
calative interaction.43 The spectral characteristics obviously
indicated that both the ligands and metal complexes interacted
with DNA most likely through an intercalation mode involving
a stacking interaction between the aromatic chromophore and
base pairs of DNA.
In order to compare the DNA-binding affinities of the ligands
and their metal complexes quantitatively, their intrinsicThis journal is © The Royal Society of Chemistry 2018binding constants Kbin were obtained according to eqn (S1).†
The binding constant value was calculated from the plot of
[DNA]/(3a  3f) versus [DNA] and the data were given in Table 3
(Fig. 8). From the results, the intrinsic DNA-binding constants
Kbin were found to be in the order Complex 3 > Complex 2 >
Complex 1 > Complex 4 > H2L
3 > H2L
2 > H2L
1 > H2L
4. This may
be due to the presence of different substituents in the terminal
nitrogen atom of the ligands. These results are comparable with
earlier reports describing the intercalative mode of various
ruthenium intercalators.30,31,44
EB-DNA quenching studies. The competitive binding exper-
iments were carried out on the EB–CT-DNA system by varying
the concentrations of the ligands and complexes to get further
information about the binding mode of compounds with DNA.
In our studies, it was noted that upon concomitant addition of
the compounds to the EB-DNA system, emission intensity
decreased progressively, indicative of competition between EB
and compounds towards CT-DNA in binding/chelation
(Fig. S26†). The reduction of the uorescence emission inten-
sity gives criteria to investigate the DNA binding propensity of
the compounds and stacking interaction (intercalation)
between the adjacent DNA base pairs.45 As shown in Fig. S26,†
the uorescence intensity of EB-DNA gradually reduced with
increasing concentrations of compounds indicating that the
metal complexes bound to DNA by competing with EB. As the
concentration of the compounds increased from 10–100 mM,
the emission band of DNA-bound EB exhibited quenching upto
19.98, 24.07, 28.36, 23.38, 27.83, 36.67, 36.99 and 28.92% of the
initial uorescence intensity together with a red shi of 2–4 nm
for H2L
1, H2L
2, H2L
3, H2L
4, complexes 1, 2, 3 and 4 respectively.
This provides a direct evidence for the intercalative binding
mode of the compounds with DNA.RSC Adv., 2018, 8, 1539–1561 | 1545
Fig. 7 Absorption titration spectra of complexes (1–4) with increasing concentrations (2.5–25 mM) of CT-DNA (Tris–HCl buffer, pH 7.2).
RSC Advances PaperFurther quantitative measurement of the magnitude of
interaction was ascertained by the classical Stern–Volmer
equation. Quenching constant KSV is used to evaluate the
quenching efficiency and is obtained from the slope of Io/ITable 3 The binding constant (Kbin) and quenching constant (KSV)
values for the interaction of the ligands H2L
1–4 and complexes (1–4)
with CT-DNA
Compounds
Binding constant
Kbin (M
1)
Quenching constant
KSV (M
1)
H2L
1 2.1246  0.308  105 2.79  0.005  103
H2L
2 3.4346  0.306  105 3.14  0.002  103
H2L
3 7.1852  0.304  105 3.95  0.009  103
H2L
4 2.1058  0.288  105 2.91  0.005  103
Complex 1 1.2544  0.304  106 4.16  0.002  103
Complex 2 1.3958  0.320  106 5.52  0.009  103
Complex 3 1.4428  0.279  106 5.62  0.003  103
Complex 4 1.0636  0.334  106 4.00  0.002  103
1546 | RSC Adv., 2018, 8, 1539–1561versus [Q] (Fig. 9) and given in Table 3. The experimental results
showed that all the Ru(II) complexes bind to DNA more strongly
than their free ligands and the quenching constant value
increased in the order 3 > 2 > 1 > 4 which also validated the
electronic absorption spectral results. Further, the calculated
KSV values of the compounds are signicant when compared to
the reported values.30,31
Viscosity measurements. Viscosity measurements are sensi-
tive to changes of DNA length and are regarded as one of the
most effective test for the binding mode of the compounds with
DNA.46,47 In order to conrm the binding modes of the free
ligands and their Ru(II) complexes with CT-DNA, viscosity
measurement study was carried out. The effects of the ligands
and metal complexes on the relative viscosity of CT DNA are
given in Fig. 10. From Fig. 10, it is obvious that the specic
viscosity of the DNA sample increases with the addition of the
compounds. Viscosity of DNA will increase while the complex
intercalates between adjacent DNA base pairs, which leads to an
increase in the separation of base pairs at the intercalation site,
resulting an increase in the overall DNA length48,49 and theThis journal is © The Royal Society of Chemistry 2018
Fig. 8 Binding isotherms of the ligands H2L
1–4 and complexes 1–4
with CT-DNA.
Fig. 9 Stern–Volmer plot of the fluorescence titration of the ligands
H2L
1–4 and complexes (1–4) (10–100 mM) with DNA-EB (10 mM).
Fig. 10 Effect of the ligands H2L
1–4 and complexes (1–4) on the
viscosity of CT-DNA. Fig. 11 Gel electrophoresis diagram showing the cleavage of super-
coiled pBR322 DNA by ligandsH2L
1–4 and complexes 1–4 in 5% DMSO
and 95% 5 mM Tris–HCl/50 mM NaCl buffer at pH 7.2 and 37 C with
an incubation time of 2 h. Lanes M: marker; Lane L1: ligand 1 (50 mM).
Lane L2: ligand 2 (50 mM); Lane L3: ligand 3 (50 mM); Lane L4: ligand 4
(50 mM); Lane 1: complex 1 (50 mM). Lane 2: complex 2 (50 mM); Lane 3:
complex 3 (50 mM); Lane 4: complex 4 (50 mM); Lane S: metal
precursor (50 mM); forms SC, NC, and LC are supercoiled, nicked
circular, and linear circular DNA, respectively.
Paper RSC Advancesabove results concluded that compounds interacted with CT-
DNA through an intercalative mode. The results showed that
the increasing rate of viscosity was different for ligands and
complexes and the complexes exhibited a higher increasing rate
due to the chelation of the ligands with Ru(II) ion. The increasedThis journal is © The Royal Society of Chemistry 2018degree of viscosity may be depending upon the substitution on
N-terminal nitrogen of the ligands and the increasing order of
viscosity of CT-DNA by the compounds is complex 3 > complex 2
> complex 1 > complex 4 > H2L
3 > H2L
2 > H2L
1 > H2L
4, which is
consistent with the above experimental results.
On the basis of above spectroscopic studies along with the
viscosity measurements, it is revealed that the ligands and their
organoruthenium(II) complexes can bind to CT DNA via an
intercalative mode and the new Ru(II) complexes bind to CT
DNA strongly than their free ligands alone.
DNA cleavage activity. The newly synthesized Schiff base
ligands H2L
1–4 and their cyclometallated ruthenium(II)
complexes (1–4) were studied for their DNA cleavage activity by
the method of agarose gel electrophoresis against supercoiled
pBR322 DNA as the substrate, in the absence of external addi-
tives in a medium of 5 mM Tris–HCl/50 mM NaCl buffer (pH
7.2). The change in the DNA structure from supercoiled form to
nicked or linear form produces change in the extent of migra-
tion in the gel. Moreover, one strand cleavage occurring in SC
form will reduce to produce a nicked circular form (NC), which
is a slower-moving form. If both strands are cleaved, linear
circular (LC) form will be generated which migrates between SC
and NC forms.50 For comparison purposes, plasmid DNA was
incubated in presence of the representative ligands (H2L
1–4) and
their corresponding complexes (14) for 3 h at 37 C. All the
compounds efficiently cleaved the supercoiled pBR322 DNA to
nicked form and linear circular form (Fig. 11). Obviously, the
DNA cleaving efficacy of the ruthenium complexes are higher
than that of the ligands, which correlates quite well with their
DNA binding affinity. From Fig. 11, we knew that the complexes
showed potent nuclease activity without any external reagent
and complex 3 with more electron donating ethyl substitution
on terminal nitrogen atom causes stronger distortion on DNA
strand leading to more efficient DNA cleavage followed by
complex 2, complex 1 and complex 4. This resulted pattern is
consistent with the DNA binding studies results.RSC Adv., 2018, 8, 1539–1561 | 1547
Fig. 12 (A) Plot of % relative fluorescence intensity (% I/Io) vs. r (r¼ [compound]/[BSA]) (B) plot of % relative fluorescence intensity (% I/Io) vs. r (r¼
[compound]/[HSA]).
RSC Advances PaperProtein binding studies. In order to investigate the binding
of BSA and its homologue HSA with the ligands and new Ru(II)
complexes, the quenching of its uorescence emission spectra
upon addition of compounds has been studied (Fig. S27 and
S28†), since the albumin solution exhibits an intense emission
band (lex ¼ 290 nm) at lem,max ¼ 345 nm (for HSA) and 346 nm
(for BSA) which is assigned to the existence of tryptophans.51,52
Addition of the compounds to BSA resulted in the quenching of
its uorescence intensity at 346 nm upto 55.22%, 43.73%,
43.92%, 39.87%, 62.61%, 71.15%, 63.19% and 58.68% forH2L
1,
H2L
2,H2L
3,H2L
4, complex 1, complex 2, complex 3 and complexTable 4 Stern–Volmer quenching constant (KSV), quenching constant
interactions of ligands and complexes (1–4) with BSA/HSA
Compounds Stern–Volmer KSV/M
1
Quenching constant
s1
BSA
(H2L
1) 1.193  0.024  104 1.193  0.024  1012
(H2L
2) 7.730  0.009  103 0.773  0.009  1012
(H2L
3) 1.464  0.018  104 1.464  0.018  1012
(H2L
4) 6.660  0.012  103 0.666  0.012  1012
Complex 1 1.674  0.040  104 1.674  0.040  1012
Complex 2 2.382  0.011  104 2.382  0.011  1012
Complex 3 1.756  0.080  104 1.756  0.080  1012
Complex 4 1.454  0.030  104 1.454  0.030  1012
HSA
(H2L
1) 1.073  0.014  104 1.073  0.014  1012
(H2L
2) 0.909  0.010  104 0.909  0.010  1012
(H2L
3) 1.424  0.016  104 1.424  0.016  1012
(H2L
4) 0.377  0.010  104 0.377  0.010  1012
Complex 1 0.741  0.010  104 0.741  0.010  1012
Complex 2 1.088  0.030  104 1.088  0.030  1012
Complex 3 1.189  0.030  104 1.189  0.030  1012
Complex 4 0.675  0.008  104 0.675  0.008  1012
1548 | RSC Adv., 2018, 8, 1539–15614 respectively with a 2–4 nm of hypsochromic shi (Fig. 12A).
The uorescence intensities of HSA decreased upto 53.86%,
46.41%, 51.00%, 28.61%, 41.01%, 50.56%, 53.45% and 39.80%
for H2L
1, H2L
2, H2L
3, H2L
4, complex 1, complex 2, complex 3
and complex 4 respectively with an increase in the concentra-
tion of the compounds, accompanied by a blue shi of 2–5 nm
(Fig. 12B). The obtained results conrmed the interaction of the
ligands and complexes with serum albumins. The absorption
spectra of the serum albumins in the absence and presence of
ligands H2L
1–4 and the complexes 1–4 are given in Fig. S29 in
the ESI.† On adding ligands and complexes 1–4 to albumins,(kq), binding constant (Kbin) and number of binding sites (n) for the
kq/M
1
Binding constant Kbin/M
1 n
1.971  0.042  103 0.8075  0.029
3.003  0.010  103 0.8915  0.011
14.11  0.030  103 0.9947  0.010
1.111  0.018  103 0.8039  0.021
2.251  0.029  104 1.0408  0.030
3.323  0.027  104 1.0478  0.031
17.49  0.030  104 1.266  0.0290
2.178  0.019  104 1.0486  0.019
2.095  0.036  103 0.8166  0.010
2.549  0.016  103 0.8599  0.017
2.615  0.019  103 0.8130  0.021
1.165  0.018  103 0.8702  0.018
2.273  0.017  104 1.1329  0.018
6.341  0.039  104 1.1859  0.004
7.194  0.041  104 1.2027  0.030
0.297  0.024  104 0.9118  0.025
This journal is © The Royal Society of Chemistry 2018
Fig. 13 (A) Stern–Volmer plot of the fluorescence titration of the ligands H2L
1–4 and complexes (1–4) (10–100 mM) with BSA (10 mM). (B) Stern–
Volmer plot of the fluorescence titration of the ligands H2L
1–4 and complexes (1–4) (10–100 mM) with HSA (10 mM).
Paper RSC Advancesthe absorbance intensity of serum albumins was decreased with
a red shi of 2 nm. The observed changes indicated a static
quenching mechanism of serum albumins by the ligands and
complexes (1–4). To obtain a quantitative insight into the
quenching progression, the Stern–Volmer quenching constant
(KSV) and the quenching constant (Kq) were calculated from the
Stern–Volmer equation using the Io/ICorr versus [Q] plot
(Table 4).53 The observed linearity in the plots (Fig. 13) indicated
the ability of the compounds to quench the emission intensity
of serum albumins and the order of quenching constant of the
compounds is complex 3 > complex 2 > complex 1 > complex 4 >
H2L
3 > H2L
2 > H2L
1 > H2L
4. The observed KSV values are
comparable to those reported for other ruthenium complexesFig. 14 (A) Scatchard plot of the fluorescence titration of the ligands H2L
plot of the fluorescence titration of the ligands H2L
1–4 and complexes (1
This journal is © The Royal Society of Chemistry 2018and this result is consistent with the pattern in DNA binding
studies.30,44 The quenching constant values for the quenching of
serum albumins by the compounds (kq z 10
12 M1 s1) sug-
gested a good binding affinity through static quenching
mechanism.53
Furthermore, the equilibrium binding constant and
number of binding sites were evaluated by using the Scatchard
equation. The Kbin values were derived from the graph between
log[(Fo  F)/F] and log[Q] (Fig. 14) and are given in Table 4.
From the results, we conrmed that the Ru(II) complexes
having a large hydrophobic area can interact more efficiently
than the ligands with serum albumins via a static pathway.
The higher binding affinity of the complexes over the ligands1–4 and complexes (1–4) (10–100 mM) with BSA (10 mM). (B) Scatchard
–4) (10–100 mM) with HSA (10 mM).
RSC Adv., 2018, 8, 1539–1561 | 1549
RSC Advances Papermay be due to the efficient binding of protein moiety with the
complexed metal ions. Here, the binding affinities of the
complexes with serum albumins followed the same order asFig. 15 Three-dimensional fluorescence spectra of BSA in the absence a
mM, [complex] ¼ 10 mM).
1550 | RSC Adv., 2018, 8, 1539–1561those with DNA binding studies, complex 3 > complex 2 >
complex 1 > complex 4 > H2L
3 > H2L
2 > H2L
1 > H2L
4. Variation
in the binding affinity of the compounds with serum albuminsnd presence of ruthenium(II) complexes 1–4 (pH 7.4, 298 K, [BSA] ¼ 10
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advancesdepends on the electron-donating ability of the ligand, i.e. the
substitution on the N-terminal nitrogen atom. The binding
capability of the compounds to serum albumins increasedFig. 16 Three-dimensional fluorescence spectra of HSA in the absence a
mM, [complex] ¼ 10 mM).
This journal is © The Royal Society of Chemistry 2018with the increase in electron-donating ability of the substit-
uent on the terminal nitrogen of the coordinated thio-
semicarbazone ligand. The obtained quenching constant andnd presence of ruthenium(II) complexes 1–4 (pH 7.4, 298 K, [HSA]¼ 10
RSC Adv., 2018, 8, 1539–1561 | 1551
RSC Advances Paperbinding constant values of these new cyclometallated ruth-
enium(II) complexes agree well with those reported for other
ruthenium(II) complexes.31,44,54–56
Conformational investigation. The conformational changes
of the protein molecular environment in the vicinity of the
uorophore functional groups have been investigated by
synchronous uorescence spectroscopy. Synchronous uores-
cence spectra show Trp residues of serum albumins only at the
wavelength interval (Dl) of 60 nm and Tyr residues only at Dl of
15 nm. For both Dl ¼ 15 and 60 nm, uorescence intensities
have been decreased with an increasing amount of compounds
(Fig. S30–S33†). However, themagnitude of quenching and shi
of wavelength are greater atDl¼ 60 nm. This result showed that
compounds interacted with both Trp and Tyr residues but in
greater magnitude with Trp residues.
Three-dimensional uorescence spectra analysis. To inves-
tigate the micro environmental changes in BSA/HSA during
interaction with the compounds, three dimensional uores-
cence spectroscopic studies have been performed. The changes
observed in 3D emission spectra and contour lines of serum
albumins in the absence and presence of ligands and complexes
are given in Fig. 15, 16, S34 and S35 in the ESI† and their cor-
responding characteristic parameters are provided in Table 5.
The emission spectra of serum albumins such as BSA and HSA
have shown three characteristic peaks – peaks A and C corre-
sponds to rst and second order Rayleigh scattering and peak B
corresponds to the spectral characteristics of Trp and Tyr resi-
dues of proteins.57 The emission intensity of Rayleigh rst order
scattering peak increased upon adding the compounds to
serum albumins. This is due to the uorophore-quencher
complex formation of serum albumins with our ligands/Table 5 Three-dimensional fluorescence spectral characteristics of BSA
Compounds
Rayleigh scattering peaks
Peak position
lex/lem (nm nm
1)
Stokes
Dl (nm) Intensit
BSA
BSA 280/280 0 637.73
BSA + H2L
1 280/280 0 681.98
BSA + H2L
2 280/280 0 704.90
BSA + H2L
3 280/280 0 764.34
BSA + H2L
4 280/280 0 751.37
BSA + complex 1 280/280 0 867.32
BSA + complex 2 280/280 0 837.83
BSA + complex 3 280/280 0 958.23
BSA + complex 4 280/280 0 741.59
HSA
HSA 280/280 0 480.02
HSA + H2L
1 280/280 0 563.09
HSA + H2L
2 280/280 0 647.85
HSA + H2L
3 280/280 0 582.94
HSA + H2L
4 280/280 0 659.33
HSA + complex 1 280/280 0 652.04
HSA + complex 2 280/280 0 790.59
HSA + complex 3 280/280 0 612.58
HSA + complex 4 280/280 0 830.46
1552 | RSC Adv., 2018, 8, 1539–1561ruthenium(II) complexes leading to an increase in the diameter
of the macromolecule which in turn resulted in the enhance-
ment of scattering effect.58 The uorescence intensity of peak ‘B’
corresponding to the tryptophan and tyrosine residues
decreased with slight blue shi. From the results, it is inferred
that the molecular microenvironment and conformational
changes of protein occurred aer interaction with the
complexes and ligands.
Antioxidant studies. Since the synthesized ligands and Ru(II)
complexes showed good DNA binding affinity, it is considered
worthwhile to investigate their antioxidant activity. It has been
reported that free radical species such as reactive oxygen species
(ROS), are involved in the pathogenesis of various diseases
through effects on DNA directly and by acting as a tumour
promoter.59,60 The DPPH free radical scavenging activity of the
ligands and complexes were studied and quantitatively antiox-
idant properties were determined by using phosphomolybdate
method. We knew that the inhibitory effects of the tested
compounds on DPPH radical are concentration dependent and
the suppression ratio increases with increasing sample
concentrations (Fig. S36†). As seen from Fig. 17, the IC50 values
of the ligands H2L
1, H2L
2, H2L
3, H2L
4, complex 1, complex 2,
complex 3, complex 4 and vitamin C (standard) are 83.17 1.50,
80.75  1.34, 67.28  1.44, 91.21  1.54, 7.13  0.23, 6.75 
0.18, 5.28  0.24, 7.39  0.14 and 98.72  1.50 respectively.
From the results, it is revealed that the complexes exhibited
good radical scavenging activity over the standard ascorbic acid
and ligands. In the phosphomolybdenum assay, the antioxidant
activity is expressed as the number of equivalents of ascorbic
acid (Table 6). The total antioxidant activity of the compounds is
in the following order complex 3 > complex 2 > complex 1 >/HSA and BSA/HSA-complexes systems
Fluorescence peaks
y (F)
Peak position
lex/lem (nm nm
1) Stokes Dl (nm) Intensity (F)
280/343 63 514.37
280/340 60 436.40
280/342 62 437.11
280/342 62 415.28
280/342 62 486.41
280/338 58 395.56
280/339 59 372.76
280/339 59 304.43
280/340 60 368.76
280/333 53 289.67
280/335 55 281.73
280/332 52 278.16
280/336 56 275.92
280/334 54 281.01
280/335 55 268.14
280/331 51 269.53
280/337 57 266.21
280/332 52 276.12
This journal is © The Royal Society of Chemistry 2018
Fig. 17 The DPPH radical scavenging activity of the ligands,
[RuHClCO(PPh3)3] and new Ru(II) complexes.
Table 6 Estimation of Total antioxidant capacity of ligands,
[RuHClCO(PPh3)3] and new Ru(II) complexes (1–4)
Compounds
mg ascorbic
acid equivalents/ml
H2L
1 33.98  0.29
H2L
2 37.10  0.43
H2L
3 40.01  0.27
H2L
4 32.90  0.57
[RuHClCO(PPh3)3] 07.02  0.08
Complex 1 54.13  0.28
Complex 2 58.27  0.46
Complex 3 62.71  0.37
Complex 4 54.99  0.65
Fig. 18 Antibacterial activity of ligands H2L
1–4, [RuHClCO(PPh3)3] and ne
the mean (n ¼ 3).
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advancescomplex 4 > H2L
3 > H2L
2 > H2L
1 > H2L
4 > ascorbic acid >
[RuHClCO(PPh3)3]. The results concluded that the metal
complexes are better antioxidants than their parent ligands
which may be due to the chelation of the ligands to metal ion.35
The radical scavenging ability of the new complexes is greater
than that of few other reported ruthenium complexes, con-
taining Schiff base ligands.9
Antimicrobial studies. The free ligands and their cyclo-
metallated ruthenium(II) carbonyl complexes were screened for
their in vitro antimicrobial activity against certain pathogenic
bacterial and fungal species at three different concentrations
using disc diffusion method. The test solutions were prepared
in 10% aqueous DMSO and the results of the antimicrobial
activities are expressed as the zone of inhibition and minimum
inhibitory concentration (MIC) and are given in Tables S4–S7 in
the ESI†, Fig. 18 and 19. From the results, we concluded that the
ligands and complexes exhibited signicant activity, but they
did not reach the effectiveness of the conventional bacteriocide
gentamicin and fungicide ketoconazole. Tested complexes had
better antimicrobial activity than the ligands against all path-
ogens. This may be explained by Tweedy's chelation theory.61
Coordination of ligands reduce the polarity of the metal ion
essentially by partial sharing of its positive charge with the
donor groups within the chelate ring system formed during the
coordination and leading to the increase in lipophilic nature of
the central metal atom, which favours the effective permeation
through the lipid layer of microorganism.61,62 On comparing the
antifungal activity of the complexes, complex 3 was more active
on four fungi namely Aspergillus niger, Aspergillus fumigatus,
Candida tropicalis and Candida albicans followed by complex 2,
complex 4 and complex 1. When tested against T. rubrum, the
activity of the complexes in the order of 3 > 2 > 1 > 4. In anti-
bacterial studies, the complex 3 was effective against S. aureus
followed by complex 2, 1 and 4 and in the case of S. pneumonie
the activity of the complexes follows the order of 3 > 1 > 4 > 2. On
comparing the activity of the complexes, complexes 2 and 3
were more active on bacteria namely P. aeruginosa. When testedw Ru(II) complexes (1–4). Error bars represent the standard deviation of
RSC Adv., 2018, 8, 1539–1561 | 1553
Fig. 19 Antifungal activity of ligandsH2L
1–4, [RuHClCO(PPh3)3] and new Ru(II) complexes (1–4). Error bars represent the standard deviation of the
mean (n ¼ 3).
RSC Advances Paperagainst S. paratyphi complex 1 stood out as good followed by the
complexes 4, 3 and 2 respectively. The compounds showed
different degrees of antimicrobial activity due to the structural
variations of themselves and variation on the group of micro-
organisms.63 In addition, antimicrobial activity of the
complexes was compared with already reported ruthenium
complexes, showing that the new Ru(II) complexes exhibited
better activity.64,65
Anticancer studies. The DNA/protein binding studies, anti-
oxidant and antimicrobial studies had shown that the ligands
and ruthenium(II) complexes studied here have therapeutic
potentials and were subjected to study their anticancer activity. AFig. 20 The newly synthesized ligands, [RuHClCO(PPh3)3] and cisplatin in
MCF-7 and A549 cells were treated with different concentrations of lig
expressed as percentage cell viability with control. Results shown are m
1554 | RSC Adv., 2018, 8, 1539–1561number of coumarin derivatives have shown considerable anti-
cancer activity against a number of cell lines. All the 3-acetyl-7-
methoxy-coumarin-4(N)-substituted thiosemicarbazone ligands,
metal precursor [RuHClCO(PPh3)3] and their new cyclo-
metallated Ru(II) complexes were assessed for their cytotoxicity
with two human derived cell lines namely human lung carci-
noma (A549) and human breast cancer cells (MCF-7) by using
MTT assay. For comparison purpose, cisplatin was used as
a positive control under identical conditions. The dose–response
curves are given in Fig. 20–22 and the results are shown in
Table 7. The IC50 values for the ligands and their complexes forhibit MCF-7 and A549 cells proliferation in a dose dependent manner.
ands for 48 h, the cell viability was determined and the results were
ean, which are three separate experiments performed in triplicate.
This journal is © The Royal Society of Chemistry 2018
Fig. 21 The newly synthesized ruthenium(II) complexes (1–4) inhibit MCF-7 and A549 cells proliferation in a dose dependentmanner. MCF-7 and
A549 cells were treated with different concentrations of complexes for 48 h, the cell viability was determined and the results were expressed as
percentage cell viability with control. Results shown are mean, which are three separate experiments performed in triplicate.
Fig. 22 The newly synthesized ligands H2L
1–4, Ru(II) complexes, [RuHClCO(PPh3)3] and cisplatin inhibit HaCaT cells proliferation in a dose
dependent manner. HaCaT cells were treated with different concentrations of compounds for 48 h, the cell viability was determined and the
results were expressed as percentage cell viability with control. Results shown are mean, which are three separate experiments performed in
triplicate.
Paper RSC Advancesthe MCF-7 and A549 showed that the ligands and their Ru(II)
complexes were cytotoxic to these cells.
Whilst most of the Schiff bases did not display good anti-
cancer activity, the coumarin appended thiosemicarbazones
H2L
1–4 against MCF-7 cell line exhibited IC50 values of 13.06 
0.29 mM, 12.12 0.32 mM, 11.27 0.21 mM and 13.11 0.25 mM
respectively, which were lower than that of cisplatin, indicating
ligands showed good activity over cisplatin. Against the human
breast cancer cell line MCF-7, the antiproliferative activity of
Ru(II) complexes 1–4 was higher than that of their parent
ligands and cisplatin with lower IC50 values of 2.86  0.17 forThis journal is © The Royal Society of Chemistry 2018complex 1, 2.62  0.07 for complex 2, 2.53  0.10 for complex 3
and 3.02  0.05 for complex 4.
The ligands H2L
1–4 and complexes exhibited high cytotoxic
effects on lung cancer cells with low IC50 values indicating their
efficiency in killing cancer cells even at low concentrations. In
A549, the anticancer activity of the compounds follows the order
ruthenium precursor (15.96  0.21) < cisplatin (15.10  0.05) <
H2L
4 (13.83 0.18) <H2L1 (12.64 0.24) <H2L2 (12.12 0.16) <
H2L
3 (11.63  0.15) < complex 4 (3.05  0.12) < complex 1 (2.96
 0.07) < complex 2 (2.93  0.07) < complex 3 (2.37  0.04).
From this study, we concluded that the coumarin-appended
Schiff base derivatives had potent activity than cisplatin used toRSC Adv., 2018, 8, 1539–1561 | 1555
Table 7 The IC50 values for the human breast cancer cell line MCF-7,
human lung carcinoma cancer cell line A549 and human normal
keratinocyte cells (HaCaT) with the ligands H2L
1–4, [RuHClCO(PPh3)3]
and new organometallic Ru(II) complexes for 48 h
Compounds
IC50 values (mM)
MCF-7 A549 HaCaT
Cisplatin 16.79  0.08 15.10  0.05 >40
H2L
1 13.06  0.29 12.64  0.17 >40
H2L
2 12.12  0.32 12.12  0.16 >40
H2L
3 11.27  0.21 11.63  0.15 >40
H2L
4 13.11  0.25 13.83  0.18 >40
[RuHClCO(PPh3)3] 20.10  0.18 15.96  0.21 >40
Complex 1 2.86  0.17 2.96  0.07 >40
Complex 2 2.62  0.07 2.93  0.07 >40
Complex 3 2.53  0.10 2.37  0.04 >40
Complex 4 3.02  0.05 3.05  0.12 >40
RSC Advances Papertreat human breast cancer and human lung cancer. In addition,
the coordination of the ligands to the Ru(II) ion increases the
anticancer activity of the complexes to six times greater than the
ligands and eight times greater than the cisplatin against both
the cell lines. Thus, the presence of the substituent at N-
terminal nitrogen seems to be important for varying the order
of activity of the compounds. In both MCF-7 and A549 cell lines,
ruthenium(II) complex 3 containing more electron donating
ethyl group at N-terminal nitrogen exhibited high activity fol-
lowed by complex 2 (NH–Me), complex 1 (NH–H) and complex 4,
which has electron withdrawing phenyl group at terminal
nitrogen atom of the ligand. On the basis of the results, the
antiproliferative activity of these compounds has been arranged
in the order 3 > 2 > 1 > 4 > H2L
3 > H2L
2 > H2L
1 > H2L
4. Inter-
estingly, this observation is in agreement with their previous
biological studies, suggesting that the anticancer activities of
the tested compounds against cancer cell lines may be related to
their ability to intercalate the base pairs of the DNA and/or their
free radical scavenging activity.Fig. 23 Percentage of lactate dehydrogenase released by the human
cancer cell lines A549 and MCF-7 after an incubation period of 48 h
with ligands H2L
1–4 and complexes 1–4. Error bars represent the
standard mean error (n ¼ 6).
1556 | RSC Adv., 2018, 8, 1539–1561In order to investigate the selectivity of the compounds for
cancer cells rather than normal cell lines, the compounds were
also screened for their anticancer activity on the human normal
keratinocyte cells (HaCaT). In the noncancerous cell line, all the
compounds showed their nontoxic nature. Furthermore, the
IC50 values exhibited by the complexes showed a higher cyto-
toxic effect when compared to the other reported Ru(II)
complexes.24,26,30,31,44,66,67
Lactate dehydrogenase release. LDH is a stable cytoplasmic
enzyme that is released into the culture medium following loss
of membrane integrity and serves as a general mean to assess
cytotoxicity resulting from chemical compounds or environ-
mental toxic factors.68 In the present study, LDH leakage into
the culture medium of the compounds treated A549 and MCF-7
cells was analyzed. It was observed that the new ligands and
their Ru(II) complexes could potently induce the release of LDH
into the culture medium of A549 and MCF-7 cells when they are
treated with their respective IC50 concentrations for 48 h,
indicating that the compounds could rupture the plasma
membrane (Fig. 23). The results conrmed the cytotoxic effect
of the ligands and complexes on lung and breast cancer cell
lines. The compounds could induce LDH leakage as high as that
of cisplatin. The induction of LDH release was found to be
higher for complexes than their parent ligands when comparing
among them and with the control. Among the compounds
examined, complex 3 was found to be more potent in inducing
LDH leakage into the culture than the rest. These results are
comparable with the earlier reports.30
Nitric oxide release. Nitrite is the stable product of the nitric
oxide released in response to oxidative stress. The amount of
nitrite in the culture medium corresponds to the level of nitric
oxide. Hence the level of nitrite is estimated to measure the NO
produced aer complex treatment. The level of nitrite was
found to increase signicantly in the ligands and Ru(II)
complexes treated A549 and MCF-7 cells compared to the
control. The increased level of nitrite in the cell culture medium
further conrms the cytotoxic effects of the presently studiedFig. 24 Nitrite released (nmoles) by the human cancer cell lines A549
and MCF-7 after an incubation period of 48 h with ligands H2L
1–4 and
complexes 1–4. Error bars represent the standard mean error (n ¼ 6).
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advancescompounds. The induction of cytotoxicity in terms of NO
release in A549 and MCF-7 cells follows the order of 3 > 2 > 1 > 4
> H2L
3 > H2L
2 > H2L
1 > H2L
4 > cisplatin. These results authen-
ticated the results obtained by MTT and LDH leakage assays
indicating that complex 3 is more effective than the remaining
three complexes (Fig. 24). The nitric oxide release by the
compounds is higher than that of cisplatin, and it is better than
those reported for other ruthenium(II) complexes containing
triphenylphosphines.30 The results of the nitric oxide assay
support the concept that the complex-induced cell death is
mediated by reactive oxygen species generation.
Conclusion
A series of ligands 3-acetyl-7-methoxycoumarin-4N-substituted
thiosemicarbazones were prepared and consecutively
made to undergo complexation with ruthenium precursor
[RuHCl(CO)(PPh3)3]. The reactions ended up in cyclometallated
organometallic Ru(II) complexes. Analytical and spectral studies
accounted for the formation of the complexes. The ligands
acted in a tridendate manner by bonding through C, N and S
atoms. A systematic study on their DNA/protein binding prop-
erties and antioxidant activities was carried out. Experimental
results suggest that the ligands and complexes can bind to DNA
via an intercalation mode and a static quenching with proteins.
Evaluation of their inhibitory potency against bacterial and
fungal pathogens revealed that the compounds possess a good
spectrum of antimicrobial activity. The in vitro cytotoxic activity
of the complexes was ascertained via MTT assay and the IC50
values were found in the range of 2.53  0.10–3.02  0.05 mM
and 2.37  0.04–3.05  0.12 mM for MCF-7 and A549 cancerous
cell lines, respectively. Moreover, LDH and NO release assays
conrm the anticancer potential of the tested compounds. The
results validated that complex 3 is a potent chemotherapeutic
drug among others. This may be attributed to the more electron
donating ability of the N-terminal ethyl group. In addition, the
present investigation lights up the potent antiproliferative effect
of ruthenium complexes by inhibiting the viability of A549 and
MCF-7 cells. Hence, further studies on animal models to
elucidate the clear mechanism of action of the complexes are
highly warranted to unveil the ruthenium complexes as anti-
cancer drugs.
Experimental section
Materials and methods
All the reagents used were of analytically or chemically pure
grade. Solvents were puried and dried according to standard
procedures.69 The metal precursor [RuHCl(CO)(PPh3)3]70
and 3-acetyl-7-methoxy-chromene-2-one (3-acetyl-7-methoxy
coumarin)71 were prepared according to the literature proce-
dure. Doubly distilled water was used to prepare buffers.
Ethidium bromide (EB), serum albumins (BSA/HSA), calf
thymus DNA (CT-DNA) and 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from
HiMedia (Mumbai, India) and used as received. Human lung
cancer cell lines A549, human breast cancer cell lines MCF-7This journal is © The Royal Society of Chemistry 2018and human normal keratinocyte cells (HaCaT) were obtained
from the National Center for Cell Science (NCCS), Pune, India.
Melting points were measured in a Lab India apparatus.
Infrared spectra were measured as KBr pellets on a JASCO FT-
IR 4100 instrument between 400–4000 cm1. Elemental anal-
ysis of carbon, hydrogen, nitrogen and sulfur was determined
by using Vario EL III CHNS at the Department of Chemistry,
Bharathiar University, Coimbatore, India. The electronic
spectra of the compounds were recorded with a JASCO V-630
spectrophotometer using DMSO as the solvent in 800–
200 nm range. Emission spectra were recorded by using JASCO
FP 6600 Spectrouorimeter. 1H NMR spectra were recorded in
DMSO at room temperature with a Bruker 400 MHz instru-
ment, chemical shi relative to tetramethylsilane. The
stability of the compounds was performed in 1% aqueous
DMSO and phosphate buffer–DMSO (99 : 1). The stability was
analyzed by monitoring the electronic spectra over 24 h at
room temperature on a JASCO 4100 spectrophotometer.
X-ray crystallography
Suitable single crystals for the ligands H2L
1–3 and complexes
(1, 2 and 4) were obtained from methanol and
dichloromethane/methanol medium respectively. Single crystal
data collections and corrections for the ligands (H2L
1–3) and
new Ru(II) complexes (1, 2 and 4) were carried out with a Gemini
Xcaliber Atlas four circle diffractometer using graphite mono-
chromated Mo Ka (l ¼ 0.71073 A˚) radiation at 295 K. All the
calculations were done by using SHELXS-200, SHELXL-2015/7
and Olex-2 programs.72
Preparation of 3-acetyl-7-methoxy-2H-chromen-2-one71
An ethanolic solution (10 cm3) of 4-methoxysalicylaldehyde
(1.22 g, 1 mmol) was taken along with the catalytic amount of
piperidine and ethylacetoacetate (1.95 g, mmol) and was
reuxed for 5 h with continuous stirring. The reaction mixture
was then cooled to room temperature, which afforded yellow
precipitate. The crude product was ltered, washed with
ethanol (3  10 cm3) and recrystallized from ethanol to yield an
yellow crystalline product. Yield ¼ 89%. Mp 118–120 C; anal.
calcd for C12H10O4: C, 66.11; H, 4.63; found: C, 66.08; H, 4.61;
UV-Vis (DMSO), lmax (3): 354 (26 868) nm (dm
3 mol1 cm1); IR
(n, cm1): n(C]O lactone) 1731, n(C]O acetyl group) 1681. 1H
NMR (400 MHz, DMSO-d6, d ppm, J Hz): d 8.628 (s, 1H, C4–H),
d 7.857–7.877 (d, J ¼ 8, 1H, C8–H), d 6.996–7.057 (m, 2H, C5–H
and C6–H), d 3.894 (s, 3H, OCH3), d 2.573 (s, 3H, CH3).
Synthesis of ((1E)-1-(1-(7-methoxy-2-oxo-2H-chromen-3-yl)
ethylidene) thiosemicarbazone) [H2-7MAC-tsc] (H2L
1)71
Thiosemicarbazide (0.417 g, 4.58 mmol) was dissolved in 30
cm3 of methanol with continuous stirring and gently heated for
a period of 30 min. This was added to a methanolic solution (20
cm3) of 3-acetyl-7-methoxy-2H-chromen-2-one (1 g, 4.58 mmol).
To this, few drops of glacial acetic acid were added and the
mixture was reuxed for 2 h with continuous stirring. The
mixture was then cooled to room temperature whereby a yellow
crystalline compound precipitated. This was collected byRSC Adv., 2018, 8, 1539–1561 | 1557
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vacuum. The compound was recrystallized from DMF–meth-
anol (1 : 9 v/v). Yellow colored ne single crystals suitable for X-
ray analysis were collected. Yield: 72%. Mp: 213 C. Anal. calcd
for C13H13N3O3S: C, 53.58; H, 4.50; N, 14.42; S, 11.00. Found: C,
53.56; H, 4.47; N, 14.41; S, 11.00%. FT-IR (n, cm1) in KBr: n(C]
O lactone) 1728, n(C]N) 1644, n(–NH2) 3279, n(–NH) 3136, n(C]
S) 831. UV-Vis (DMSO), lmax (3): 276 (20 943) nm (dm
3
mol1 cm1); 354 (30 488) nm (dm3 mol1 cm1). 1H NMR (400
MHz, DMSO-d6, d ppm, J Hz): d 7.986 (s, 1H, C4–H), d 7.719–
7.740 (d, 1H, J ¼ 8.4, C5–H), 7.039–7.094 (m, 2H, Ar–H), d 3.931
(s, 3H, –OCH3), d 2.302 (s, 3H, –CH3), d 10.424 (s, 1H, NH–C]S),
d 8.477 & 8.409 (2 br s, 2H, –NH2).
The very similar method was followed to synthesize the
following compounds.Synthesis of ((1E)-1-(1-(7-methoxy-2-oxo-2H-chromen-3-yl)
ethylidene) 4(N)-methyl thiosemicarbazone) [H2-7MAC-mtsc]
(H2L
2)
The ligand [H2-7MAC-mtsc] was prepared from 4-(N)-methyl-
thiosemicarbazide (0.481 g, 4.58 mmol) and 3-acetyl-7-methoxy-
2H-chromen-2-one (1 g, 4.58 mmol) in the presence of glacial
acetic acid. Single crystals suitable for X-ray diffraction studies
were obtained by recrystallisation of ligand H2L
2 in methanol.
Yield: 73%. Mp: 117 C anal. calcd for C14H15N3O3S: C, 55.05; H,
4.96; N, 13.76; S, 10.49. Found: C, 55.03; H, 4.93; N, 13.71; S,
10.48%. FT-IR (n, cm1) in KBr: n(C]O lactone) 1714, n(C]N)
1608, n(terminal –NH) 3262, n(–NH) 3210, n(C]S) 834. UV-Vis
(DMSO), lmax (3): 275 (24 094) nm (dm
3 mol1 cm1); 352
(33 647) nm (dm3 mol1 cm1). 1H NMR (400 MHz, DMSO-d6,
d ppm, JHz): d 8.314 (s, 1H, C4–H), d 7.684–7.705 (d, J¼ 8.4, 1H,
C5–H), 6.985–7.029 (m, 2H, Ar–H), d 3.879 (s, 3H, –OCH3),
d 2.244 (s, 3H, –CH3), d 10.377 (s, 1H, NH–C]S), d 8.465–8.490
(q, 1H, terminal –NH), d 3.027–3.037 (d, J ¼ 4, 1H, terminal
–NH–CH3).Synthesis of ((1E)-1-(1-(7-methoxy-2-oxo-2H-chromen-3-yl)
ethylidene) 4(N)-ethyl thiosemicarbazone) [H2-7MAC-etsc]
(H2L
3)
The ligand [H2-7MAC-etsc] was prepared from 4-(N)-ethyl-
thiosemicarbazide (0.546 g, 4.58 mmol) and 3-acetyl-7-methoxy-
2H-chromen-2-one (1 g, 4.58 mmol) in the presence of glacial
acetic acid. The compound was recrystallised by using meth-
anol to yield suitable yellow crystals for X-ray analysis. Yield:
76%. Mp: 174 C. Anal. calcd for C15H17N3O3S: C, 56.40; H,
5.37; N, 13.15; S, 10.05. Found: C, 56.37; H, 5.34; N, 13.11; S,
10.01%. FT-IR (n, cm1) in KBr: n(C]O lactone) 1725, n(C]N)
1606, n(terminal –NH) 3241, n(–NH) 3155, n(C]S) 835. UV-Vis
(DMSO), lmax (3): 276 (14 245) nm (dm
3 mol1 cm1); 353
(21 388) nm (dm3 mol1 cm1). 1H NMR (400 MHz, DMSO-d6,
d ppm, JHz): d 8.291 (s, 1H, C4–H), d 7.694–7.715 (d, J¼ 8.4, 1H,
C5–H), d 7.679–7.034 (m, 2H, Ar–H), d 3.881 (s, 3H, –OCH3),
d 2.247 (s, 3H, –CH3), d 10.269 (s, 1H, NH–C]S), d 8.472–8.499
(t, J ¼ 5.6, 1H, terminal –NH), d 3.593–3.622 (p, 2H, terminal
–NH–CH2), d 1.136–1.172 (t, J ¼ 7.2, 3H, –CH3).1558 | RSC Adv., 2018, 8, 1539–1561Synthesis of ((1E)-1-(1-(7-methoxy-2-oxo-2H-chromen-3-yl)
ethylidene) 4(N)-phenyl thiosemicarbazone) [H2-7MAC-ptsc]
(H2L
4)
The ligand [H2-7MAC-ptsc] was prepared from 4-(N)-phenyl-
thiosemicarbazide (0.766 g, 4.58 mmol) and 3-acetyl-7-methoxy-
2H-chromen-2-one (1 g, 4.58 mmol) in the presence of glacial
acetic acid. The compound was recrystallised by using meth-
anol. Yield: 77%. Mp: 186 C. Anal. calcd for C19H17N3O3S: C,
62.10; H, 4.67; N, 11.43; S, 8.72. Found: C, 62.07; H, 4.64; N, 11.4;
S, 8.69%. FT-IR (n, cm1) in KBr: n(C]O lactone) 1700, n(C]N)
1600, n(terminal –NH) 3241, n(–NH) 3114, n(C]S) 826. UV-Vis
(DMSO), lmax (3): 282 (27 646) nm (dm
3 mol1 cm1); 356
(41 701) nm (dm3 mol1 cm1). 1H NMR (400 MHz, DMSO-d6,
d ppm, JHz): d 8.458 (s, 1H, C4–H), d 6.691–7.524 (m, 8H, Ar–H),
d 3.885 (s, 3H, –OCH3), d 2.332 (s, 3H, –CH3), d 10.777 (s, 1H,
NH–C]S), d 10.126 (s, 1H, terminal –NH).Synthesis of new ruthenium(II) complexes
Synthesis of [Ru(7MAC-tsc)(CO)(PPh3)2] (1). A solution of
[H2-7MAC-tsc] (0.021 g; 0.105 mmol) in 10 cm
3 of benzene was
added dropwise to a boiling solution of [RuHCl(CO)(PPh3)3]
(0.100 g, 0.105 mmol) in benzene and reuxed for 7 h and
allowed to stand for 4 days at room temperature. Reddish
orange solid formed was ltered, washed with petroleum ether
(60–80 C) and crystallized from dichloromethane and meth-
anol mixture (1 : 1 v/v) to yield red transparent needle like
crystals suitable for X-ray analysis. Yield: 66%. Mp: 247 C. Anal.
calcd for C50H41N3O4P2RuS: C, 63.67; H, 4.39; N, 4.45; S, 3.39.
Found: C, 63.64; H, 4.37; N, 4.42; S, 3.37%. FT-IR (n, cm1) in
KBr: n(C]O lactone) 1685, n(C]N) 1607, n(C–S) 745, n(C^O)
1918, 1436, 1090, 696 (for PPh3). UV-Vis (DMSO), lmax (3): 337
(33 654) nm (dm3 mol1 cm1) (LMCT s / d). 1H NMR (400
MHz, DMSO-d6, d ppm, J Hz): d 7.150–7.547 (m, 31H, Ar–H),
d 6.290–6.444 (m, 2H, C6–H and C8–H), d 3.842 (s, 3H, –OCH3),
d 1.977 (s, 3H, –CH3), d 5.651 (br s, 2H, –NH2).
A similar method was followed to synthesize other ruth-
enium(II) complexes.
Synthesis of [Ru(7MAC-mtsc)(CO)(PPh3)2] (2). Complex 2
was prepared by the same procedure as described for 1, with
H2L
2 (0.105 mmol) as a ligand. Needle shaped, transparent pink
colour crystals were obtained on slow evaporation of the reac-
tion mixture. Yield: 62%. Mp >300 C. Anal. calcd for C51H43-
N3O4P2RuS: C, 64.00; H, 4.45; N, 4.39; S, 3.34. Found: C, 63.97;
H, 4.43; N, 4.36; S, 3.30%. FT-IR (n, cm1) in KBr: n(C]O
lactone) 1680, n(C]N) 1606, n(C–S) 744, n(C^O) 1925, 1404,
1087, 695 (for PPh3). UV-Vis (DMSO), lmax (3): 268 (45 067) nm
(dm3 mol1 cm1) (intraligand transition); 363 (20 485) nm
(dm3 mol1 cm1) (LMCT s/ d). 1H NMR (400 MHz, DMSO-d6,
d ppm, J Hz): d 7.139–7.637 (m, 31H, Ar–H), d 6.62–6.63 (m, 1H,
C8–H), d 6.87–6.90 (dd, 1H, J ¼ 2.4, 8.8, C6–H), d 3.842 (s, 3H,
–OCH3), d 2.098 (s, 3H, –CH3), d 5.972–6.098 (q, 1H, terminal
–NH), d 1.221 (s, 3H, –NH–CH3).
Synthesis of [Ru(7MAC-etsc)(CO)(PPh3)2] (3). Complex 3 was
prepared by the same procedure as described for 1 with H2L
3
(0.105 mmol) as a ligand. Red solid formed was ltered, washed
with petroleum ether (60–80 C) and crystallized fromThis journal is © The Royal Society of Chemistry 2018
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62%. Mp 237 C. Anal. calcd for C52H45N3O4P2RuS: C, 64.31; H,
4.68; N, 4.32; S, 3.30. Found: C, 63.29; H, 4.64; N, 4.29; S, 3.28%.
FT-IR (n, cm1) in KBr: n(C]O lactone) 1681, n(C]N) 1606,
n(C–S) 745, n(C^O) 1923, 1432, 1087, 695 (for PPh3). UV-Vis
(DMSO), lmax (3): 268 (16 367) nm (dm
3 mol1 cm1) (intra-
ligand transition); 357 (38 703) nm (dm3 mol1 cm1) (LMCT s
/ d). 1H NMR (400 MHz, DMSO-d6, d ppm, J Hz): d 7.216–7.634
(m, 31H, Ar–H), d 6.644–6.921 (m, 2H, C6–H and C8–H), d 3.774
(s, 3H, –OCH3), d 1.887 (s, 3H, –CH3), d 6.18–6.23 (t, 1H, terminal
–NH), d 1.126–1.288 (m, 2H, J¼ 4.8, –NH–CH2), d 0.701–0.737 (t,
3H, J ¼ 7.2, –CH2–CH3).
Synthesis of [Ru(7MAC-ptsc)(CO)(PPh3)2] (4). Complex 4 was
prepared by the same procedure as described for 1 with H2L
4
(0.105 mmol) as a ligand and [RuHCl(CO)(PPh3)3] (0.105 mmol).
Red solid formed was ltered, washed with petroleum ether
(60–80 C) and crystallized from dichloromethane and meth-
anol to yield pink crystals. Yield: 60%.Mp 230 C. Anal. calcd for
C56H45N3O4P2RuS: C, 65.99; H, 4.45; N, 4.12; S, 3.14. Found: C,
65.96; H, 4.42; N, 4.09; S, 3.12%. FT-IR (n, cm1) in KBr: n(C]O
lactone) 1681, n(C]N) 1606, n(C–S) 744, n(C^O) 1920, 1431,
1089, 694 (for PPh3). UV-Vis (DMSO), lmax (3): 278 (19 763) nm
(dm3 mol1 cm1) (intraligand transition); 365 (10 531) nm
(dm3 mol1 cm1) (LMCT s / d), 380 (10 424) nm (dm3
mol1 cm1) (LMCT s / d). 1H NMR (400 MHz, DMSO-d6,
d ppm, J Hz): d 6.909–7.324 (m, 36H, Ar–H), d 6.635–6.757 (m,
2H, C6–H & C8–H), d 3.793 (s, 3H, –OCH3), d 1.957 (s, 3H, –CH3),
d 8.488 (s, 1H, terminal –NH).
Biomolecular interaction studies
The stability of the compounds was performed in 1% aqueous
DMSO and phosphate buffer : DMSO (99 : 1). The stability was
analyzed by monitoring the electronic spectra for the period of
24 h at room temperature on a JASCO 4100 spectrophotometer.
DNA binding studies, EB-displacement assays, DNA viscosity
studies, DNA cleavage experiments and protein binding studies
have been done according to the reported methods.30,31,35,44,73
The detailed procedures for these experiments are provided in
the ESI.†
In vitro antioxidant assays
The DPPH radical scavenging activity of the compounds have
been carried out according to the reported method.74 In this
study, various concentrations of the experimental standard
ascorbic acid, [RuHCl(CO)(PPh3)3], ligands (20–100 mM) and
complexes (2–10 mM) in methanol were taken. Total antioxidant
activity of the compounds was determined by the phosphomo-
lybdate method.75
In vitro antimicrobial assay
Antimicrobial activities of [RuHClCO(PPh3)3], ligands H2L
1–4
and new organometallic Ru(II) complexes (1–4) were evaluated
by agar well diffusion method76 as reported, by taking Staphy-
lococcus aureus, Streptococcus pneumonie, Pseudomonas aerugi-
nosa, Salmonella paratyphi and fungus such as Candida albicans,
Trichophyton rubrum, Aspergillus niger, Aspergillus fumigatus andThis journal is © The Royal Society of Chemistry 2018Candida tropicalis. The above said all test organisms were ob-
tained from the MTCC, Chandigarh, India and Microbiological
laboratory, Coimbatore, Tamil Nadu, India. The antimicrobial
activity of the test compounds was checked with various
concentrations (25 mg ml1, 50 mg ml1 and 100 mg ml1)
against all the test pathogens. Gentamicin and ketoconazole
were used as positive controls to study the antibacterial and
antifungal activities respectively. Each experiment was per-
formed in triplicate and the results are represented as average
zone of inhibition andminimum inhibitory concentration of all
the test pathogens.Cytotoxicity studies
Cytotoxic activity of the compounds was tested with human
lung cancer cell lines A549, human breast cancer cell lines MCF-
7 and human normal keratinocyte cells (HaCaT) by using MTT
assay, which was done according to the earlier literature
methods77 and IC50 values obtained from nonlinear regression
using GraphPad Prism 5.78 The LDH release79 and NO release80
assays of the compounds was evaluated by the earlier reported
methods.Conflicts of interest
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